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Objectives We aimed to evaluate the safety and feasibility of a robotic angioplasty system in deliv-
ery and manipulation of coronary guidewires, balloons, and stents in patients undergoing elective
percutaneous coronary intervention (PCI).
Background A remote-control, robotic-assisted angioplasty system is under development to address
some of the procedural challenges and occupational hazards associated with traditional PCI.
Methods Patients with coronary artery disease and clinical indication for elective PCI were enrolled.
The coronary angioplasty procedure was performed with the CorPath 200 robotic system (Corindus,
Inc., Natick, Massachusetts). The system consists of a remote interventional cockpit and a multicom-
ponent bedside unit that enables the operator to advance, retract, and rotate guidewires and rapid
exchange catheters. The primary endpoint was device clinical success (30% residual stenosis) with-
out in-hospital major adverse cardiac events. Technical success was deﬁned as the ability of the sys-
tem to complete all the planned angioplasty steps on the basis of procedural segments. Patients
were followed up to 30 days after angioplasty procedure.
Results A total of 8 patients were enrolled in the study. The primary endpoint was achieved in all
patients (100%). The technical success of the robotic system was 97.9% in completing 47 of 48
planned steps. There were no device- or procedure-related complications and no in-hospital or
30-day major adverse cardiac events. The operators rated the robotic system performances as equal
to or better than manual procedures in 97.5% of the cases. The operator radiation exposure was
97% lower than the levels found at the standard table position.
Conclusions Early clinical experience with a robotic-assisted angioplasty system demonstrated feasi-
bility, safety, and procedural effectiveness comparable to manual operation. In addition, the total
operator exposure to radiation was signiﬁcantly low. A larger study is warranted to verify the safety
and effectiveness of robotic-assisted percutaneous coronary intervention. (J Am Coll Cardiol Intv
2011;4:460–5) © 2011 by the American College of Cardiology Foundation
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461The current practice of percutaneous coronary intervention
(PCI) still presents potential hazards for patients, operators,
and the catheterization laboratory personnel (1–3). With the
increasing complexity of the treated lesions and procedures,
both patients and laboratory personnel are subjected to longer
procedural duration and radiation exposure (3). From the
operator perspective, the long hours of standing while wearing
a lead apron commonly leads to orthopedic injuries that fre-
quently results in reduced performance and loss of workdays (1).
A remote-control, robotic-assisted angioplasty system was
eveloped to address some of the procedural challenges and
ccupational hazards associated with traditional PCI in addi-
ion to enhancing the degree of precision and control for the
nterventional procedure. We report the first-in-human expe-
ience with a novel, robotic system for PCI. The objective of
he study was to evaluate the safety and feasibility of the system
n delivery and manipulation of coronary guidewires, balloons,
nd stents in patients undergoing elective PCI.
ethods
This first-in-human study was designed as a single-arm, open-
label, prospective investigation of a robotically assisted angioplasty
system among patients undergoing PCI. All procedures were
performed at the Corbic Research Institute (Corbic Institute,
Envigado, Colombia). The study protocol was approved by the
local ethics committee and the Ministry of Health of Colombia,
South America.
Study population. Patients with angiographic documenta-
ion of obstructive coronary artery disease and evidence of
yocardial ischemia were enrolled in the study. All patients
ad a single de novo coronary target lesion, up to 25 mm in
ength, in vessels ranging from 2.5 to 4.0 mm in diameter.
ajor clinical exclusion criteria included planned coronary
rtery bypass graft surgery or PCI within 30 days of target
rocedure, congestive heart failure or left ventricular ejection
raction of 30%, recent (72 h) myocardial infarction, and
ecent stroke (30 days) or bleeding diathesis. Angiographic
xclusion criteria included prior stent within 5 mm of the target
esion, ostial or bifurcation lesion, total occlusion, and severe
ortuosity or calcification. All patients were individually fol-
owed for clinical events for 30 days after procedure.
Robotic PCI system. The CorPath 200 System (Corindus,
nc., Natick, Massachusetts) is a novel robotic system that
as developed for coronary and endovascular procedures
Fig. 1). The system consists of 2 major components: the
nterventional cockpit and a bedside unit. The interven-
ional cockpit is a radiation-shielded mobile workstation
hat can be positioned anywhere in the catheterization
aboratory. It allows the interventional cardiologist to per-
orm the PCI procedure remotely from the control console
hile sitting at the cockpit unit. The robotic system is an
pen-architecture system that is compatible with 0.014-inch
uidewires, rapid exchange catheter systems, and othertandard catheterization laboratory hardware and imaging
ystems (Fig. 1B). The system allows manipulation of the
uidewire, balloon, and/or stent catheter with 1 hand with the
ossibility of operating the automatic contrast media injector
ith the other hand. Manipulation is achieved through the
esignated joysticks at the control console (Fig. 2A). The
uoroscopy and electrocardiography and hemodynamic mon-
tors are “slaved” to duplicate monitors inside the cockpit,
nabling visualization from a closer distance (Fig. 2B). The
edside unit includes the bedrail-mounted articulated arm
upporting the robotic drive with the attached single-use
assette. The robotic drive is connected to the control
onsole with a communication cable.
Robotic-assisted angioplasty procedure. Baseline angiograms
nd the suitability of the target lesion for robotically assisted PCI
ere analyzed before intervention. The procedure was started by
btaining vascular access through conventional percutaneous cath-
terization techniques. A standard guiding catheter was manually
ntroduced, and the target coronary artery was selectively cannu-
ated by the operator with standard interventional techniques. The
uide catheter is manually connected to the Y-connector,
hich—in its turn—is placed manually into the Y-connector
older of the cassette. A part of the guide catheter between the
-connector and incision site was
upported by the adjustable robotic
xtension arm. The coronary guide-
ire was manually introduced
hrough the Y-connector into the
uiding catheter and loaded the dis-
al end of the guidewire into the
assette. From this point forward,
he operator, via the control console joysticks is capable of
ontrolling the cassette, which offers linear and rotational motions,
o the devices can be advanced, retracted, and rotated. After
oronary guidewire introduction with the robotic system, the
perator loaded a rapid exchange coronary angiography balloon
nto the system and advanced the device with the robotic system
o perform pre-dilation of the target lesion by a standard tech-
ique. Thereafter, the angioplasty balloon was retracted with the
obotic system and then exchanged for a rapid exchange stent
elivery system. The procedure for stent insertion, deployment,
nd retrieval was performed with the robotic system in a similar
ashion. Final angiography was performed from the cockpit to
ssess the efficacy of stent implantation and rule out the presence
f any associated complications.
Study endpoints. The primary endpoint was device clinical
success, defined as 30% final diameter stenosis after using
the robotic angioplasty system to deliver a balloon and
deploying a stent to the target lesion, and successfully
retracting the delivery system without in-hospital major
adverse cardiac events (MACE). Major adverse cardiac
events were defined as cardiac death, Q-wave or non–Q-wave
myocardial infarction, or clinically driven target vessel revascu-
Abbreviations
and Acronyms
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary interventionlarization. Technical success was defined as the ability of the
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462Figure 1. CorPath 200 System
Description of the CorPath 200 System. (A) Typical set up of the equipment in the catheterization laboratory: bedside unit mounted on a bedrail, and the Inter-
ventional Cockpit is positioned at the foot of the procedure table. (B) The bedside unit is composed of: 1–an articulated arm containing 2–the robotic drive; and
3–a single-use cassette. The 4–single-use cassette, shown with 5–attached guide catheter supported with guide catheter arm and 6–loaded balloon catheter.
botic s
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463system to complete all the planned technical steps on the basis
of the number of procedural segments required to complete the
introduction and retrieval of all devices. Radiation exposure to
the operator at the cockpit and at the procedure table—a site of
traditional operator—was monitored with the electronic direct
dosimeters (EDD-30, Unfors, Billdal, Sweden). The robotic-
system procedural attributes were recorded immediately after the
procedure and were rated by all operators as better, equal, or worse
than manual separately for the guidewire, balloon catheter, and
balloon/stent catheter in 5 performance categories: introduction,
tractability, pushability, crossing lesion, and withdrawal.
Statistical analysis. Data were manually entered in Excel
spreadsheet (Microsoft, Redmond, Washington), and with Excel
software, the following values were calculated: average (mean),
SD, and median. The radiation exposure for the operator at
the interventional cockpit and at the procedure table as well
as creatine kinase-myocardial band values from before and
24 h after procedure were analyzed with Wilcoxon paired
Figure 2. CorPath 200 System Console
(A) Representative picture of the control console: 1–touch screen controls; 2–guidewi
tional cockpit with control console for manipulating percutaneous transluminal corona
at his eye level. (C) A guidewire and then a 2.5-  9-mm balloon were advanced thro
form pre-dilation. A 2.5-  16-mm stent was delivered to the target lesion with the rononparametric test, due to a small sample size (n  8).Results
A total of 8 patients who met inclusion and exclusion
criteria and had signed the informed consent form under-
went PCI with the robotic system. Table 1 summarizes the
demographic and baseline characteristics of all included
patients. The left anterior descending artery was treated in
1 patient (12.5%), the right coronary artery was treated in 4
patients (50%), and the left circumflex artery was treated in
3 (37.5%). Six selected lesions were classified as type A, and
2 were classified as Type B1 lesions, in accordance with
American College of Cardiology/American Heart Associa-
tion grading criteria. The mean lesion length was 11.4 6.1
mm, mean reference vessel diameter was 3.0  0.74 mm,
and the mean diameter stenosis was 63.1  15%. All
procedures were performed with a 6-F guide catheter and a
single type 0.014-inch balanced middleweight wire (Abbott
Vascular, Santa Clara, California). Pre-dilation was done
tick; and 3–balloon/stent catheter joystick. (B) The operator seated at the interven-
ioplasty devices and the angiography and hemodynamic signs monitors positioned
proximal posterior descending artery lesion with the robotic angioplasty arm to per-
ystem and deployed in a standard fashion.re joys
ry ang
ugh awith the monorail Maverick2 balloon (Boston Scientific,
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464Natick, Massachusetts). The stents used were either bare-
metal (Liberté, 75%) or the everolimus-eluting stent (Pro-
mus, 25%) (both Boston Scientific). At the end of the
procedures, all patients had final residual stenosis of 10%
with Thrombolysis In Myocardial Infarction flow grade 3.
All PCI procedures were completed with the robotic system
without any periprocedural complications. An example of the
lesions treated is shown in Figure 2B. The mean procedure time
was 43.0 18.6 min with mean robotic-system procedure time of
26.5 8.0 min and with a mean fluoroscopy time of 11.5 3.7
min. In all patients the robotic-assisted procedure included suc-
cessful navigation and crossing the target lesion. The advance-
ments of the guidewire proceeded smoothly, without any dissec-
tion or perforation. In all patients the pre-dilation balloon was
successfully delivered to the lesion, inflated as clinically indicated,
and successfully retrieved by the robotic system back into the
guiding catheter. In all the patients the stent was successfully
delivered to the lesion by the system. After stent deployment, in all
patients, the stent delivery system was successfully retrieved into
the guiding catheter. In all but 1 patient, the guidewire was
successfully retrieved into the guide catheter. In 1 patient, the
guidewire was retrieved by the robotic system to the distal part of
the guide catheter, but because of a partial system malfunction, the
rest of the retrieval was performed manually. This conversion to
manual operation was immediate and not associated with myo-
cardial ischemia, hemodynamic compromise, or any other com-
plications. In summary, 100% of the interventional components
were successfully delivered, and 95.8% (23 of 24) were successfully
retrieved, for an overall technical success rate of 97.9% (47 of 48).
There were no clinical adverse affects related to the use of the
robotic system. Thus, the primary endpoint defined as device
clinical success (30% residual stenosis) without in-hospital
MACE was achieved in all 8 patients (100%). At 24 h after
procedure, no patient had increase in the creatine kinase-
Table 1. Demographic Data and Procedural Characteristics of
All Patients Intervened
Mean age (yrs) 67.8 10.7
Female 62.5%
Hypertension 75%
Diabetes mellitus 37.5%
Hyperlipidemia 75%
Prior myocardial infarction 25%
Prior PCI 25%
Prior CABG 0%
Left ventricular ejection fraction 59.4 8.6%
Total contrast volume used (ml) 158.8 53.8
Procedural radiation exposure
Table (Gy) 61.57 54.95
Operator (Gy) 1.81 1.93
Patient (mGy) 2,079 800
Values are mean SD or %.
CABG coronary artery bypass graft surgery; PCI percutaneous coronary intervention.myocardial band levels (mean levels changed from 14.6  3.2 at vbaseline to 16.1 3.6 at 24 h, p 0.35). There were no instances
of in-hospital MACE, and at 30-day follow-up, all patients
remained asymptomatic with no MACE. Total radiation expo-
sure to the operator at the cockpit was 97% lower than at the
procedure table (1.81 1.93 Gy vs. 61.57 54.95 Gy; p
0.012).
The robotic system performance during PCI procedure
was rated as equal to that of the manual procedure in 92.5%
of the cases for all devices and procedural steps. In 2 cases,
the guidewire advancement/retrieval was rated as better
than manual, and in the single case of guidewire retrieval
failure, it was rated as worse than manual.
Discussion
In this study we report the first-in-man experience with the
CorPath 200 System, a novel robotic-assisted angioplasty
system. The system achieved a technical success rate of
97.9%, completing 47 of 48 procedural segments, and there
were no MACE or any other adverse events associated with
the system. All patients were discharged home within 24 h
after intervention. In 1 case, at the end of the procedure
after successful deployment of the stent and at the time of
the final wire retrieval, there was a recoverable cassette
failure, and the operator decided not to complete the
procedure with the robotic-assisted system and removed the
remainder of the wire (approximately 2 cm) manually. This
system malfunction was considered minor and did not
compromise the overall performance and safety of the
procedure at any given point. Except for this 1 case, the
operators consistently scored the robotic-assisted system at
least equal to manual operation. All the patients completed
the 30-day follow-up without MACE.
Robotic systems have been suggested to enhance the precision
of cardiovascular procedures with increased accuracy (4–10). One
of the technical features of the robotic system is the capability to
control and accurately position (1-mm steps) the stent delivery
system. The recent STLLR (Stent deployment Techniques on
cLinicaL outcomes of patients treated with the cypheRstent) trial
highlighted the impact on clinical outcomes of geographic miss
and stent misplacement (11). Although endovascular imaging
guidance is likely necessary to improve the precision of stent
placement, the robotically assisted system facilitates the position-
ing of the stent delivery system with a high degree of accuracy. In
addition, robotic systems have been suggested to reduce radiation
exposure (12,13). The RELID (Retrospective evaluation study
of lens injuries and dose) study revealed that interventional
cardiologists have cataract-type eye opacities 3 times more
often than age-matched controlled group (2). The mean
fluoroscopy time from this study compares favorably with the
results of the study of 9,650 patients undergoing single-vessel
PCI (11.5 min vs. 18.3 min) (14) and with a sub-group of
7,242 patients whose fluoroscopy time was23 min (11.5 min
s. 12.7 min) (14). Shorter fluoroscopy time translated into
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465reduced radiation exposure for the patient and the operator and
reduced contrast fluid usage. In our study, 1 of the most
important findings was the significant (97.1%) reduction in
radiation exposure to the operator performing the robotic PCI
procedure. The patient radiation exposure was within the
normal reported limits: 2.1 Gy versus 1.9 Gy (14). Also,
although the study was not designed to show differences in
contrast volume usage, the total volume of contrast agents used
in this study seemed to be less, compared with what has been
reported in other clinical series (14). The lower contrast usage
might be attributed to the complete procedure control enabled
by the interventional cockpit environment (Fig. 2). Another
subjective but still important finding was the level of technical
“comfort” expressed by the operators. Although no specific
measurement of this variable was used in this study, both
operators perceived this system to be more comfortable com-
pared with the typical technique used for coronary interven-
tion. Most of the cases were performed under a controlled
environment, in which the operator had the opportunity to
focus on the performance of the procedure, having a close
proximity of the monitors and not distracted by the physical
strain of the lead apron and standing position.
Despite the significant evolution in interventional device tech-
nologies, the actual procedural methodology and workflow in the
catheterization laboratory has remained unchanged in the last 25
years. As the current practice of interventional cardiology evolves
into more complex PCI procedures, interventional cardiologists,
the professional societies (15), U.S. Food and Drug Administra-
tion, and International Atomic Energy Agency called for en-
hanced catheterization laboratory safety by reducing radiation
exposure to both patients and operators (16–17) and making the
overall catheterization laboratory environment more ergonomi-
cally friendly through technological innovations (3). Incorporating
a remote-control, robotic-assisted PCI system into the catheter-
ization laboratory might address some of the procedural deficien-
cies and occupational hazards associated with traditional PCI in
addition to contributing to a higher degree of precision and
control for the interventional procedure.
In this early clinical experience, the use of the robotic system
seems not to reduce the overall periprocedural times compared
with manual PCI of single lesions (14). However, we believe
that, as this technology underwent initial clinical evaluation,
the rigor of the study procedure in addition to the time
required to register the data added additional procedural time.
In addition, from the operator point of view, there was an
initial learning and technology adaptation curve that we believe
will improve over time, leading to shorter procedural times.
However, this study still represents an early feasibility study in
a small cohort of patients, and the use of this technology in more
challenging anatomies including the presence of severe tortuosity,
severe calcification, or interventions requiring multiple wires and
balloons needs to be further studied. A larger, prospective, multi-
center pivotal clinical trial designed to test the robotic angioplasty
system in a larger number of patients is underway.Reprint requests and correspondence: Dr. Juan F. Granada,
Skirball Center for Cardiovascular Research, Cardiovascular Re-
search Foundation, 8 Corporate Drive, Orangeburg, New York
10962. E-mail: jgranada@crf.org.
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